About this trial
Patient Profile
Patients with melanoma who have had prior neo/adjuvant PD-(L)1 more than 6 months before enrolment
Where’s this trial being run?
St Vincents University Hospital
Can I join this study / trial?
The first thing you do is to talk to your doctor and/or the cancer trials research team in your hospital. The contact details for the cancer trials research units in Ireland is here.
Why not Print this page and bring it with you. It will help your doctor and research team advise you.
Print this pageFor more detailed information
Click HereQuestions?
Here’s a list of questions you may have for your doctor or local cancer research team.
QuestionsSummary Data
| Name: | R3767-ONC-1613 |
|---|---|
| Number: | CTRIAL-IE 20-11 |
| Full Title: | Study of REGN3767 (Anti-LAG-3) With or Without REGN2810 (Anti-PD1) in Advanced Cancers: A Phase 1, Open-Label, Dose-Escalation and Cohort Expansion First-in-Human Study of the Safety, Tolerability, Activity and Pharmacokinetics of REGN3767 (Anti-LAG-3 mAb) Administered Alone or in Combination With REGN2810 (Anti-PD-1 mAb) in Patients With Advanced Malignancies |
| Principal Investigator: | Ray McDermott |
|---|---|
| Type: | Industry Sponsored |
| Sponsor: | Regeneron |
| Recruitment Started: |
Global: Nov 2016 Ireland: 2019 |
| Global Recruitment Target: | 669 |
|---|---|
| Ireland Recruitment Target: |